Thus, SUMOylation of SERCA2a activated via small molecules or enforced expression of SUMO1 with gene transfer may be a new therapeutic approach to treat heart failure.69 The SUMOylation of HSF2 mediated by SUMO‐1 was reported to attenuate myocardial hypertrophy. The gene discussed is SUMO1; the disease is heart failure.